Blood-based biomarker could help stratify cancer risk in Lynch Syndrome

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch Syndrome (LS) who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians to stratify patients based on their personal risk level.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup